Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes
CONCLUSION: The 24-week treatment with oral semaglutide ameliorated glycemic control with reduction of body fat but not muscle mass in Japanese patients with type 2 diabetes.PMID:37575352 | PMC:PMC10416191 | DOI:10.14740/jocmr4987
Source: Clin Med Res - Category: Research Authors: Syutaro Uchiyama Yukiyoshi Sada Syohei Mihara Yosuke Sasaki Masakatsu Sone Yasushi Tanaka Source Type: research
More News: Diabetes | Diabetes Type 2 | Endocrinology | Insulin | Japan Health | Laboratory Medicine | Research | Study | Victoza | Weight Loss